For Healthcare Providers
Syndromic Testing Puts Patient Care Front and Center
At GenMark, we believe in the syndromic approach to diagnosis of infectious diseases. Our panels are designed to rapidly detect several of the most common pathogens that cause disease using a single patient sample, allowing clinicians to provide appropriate treatment earlier than with conventional testing methods. In some cases, this may mean a patient does not get treated with an antimicrobial agent unnecessarily, eliminating potential adverse side effects that may come from some treatments. It also can result in better patient outcomes, more rapid infection control and hospital bed management actions, as well as improved patient satisfaction.
Designed for the Patient
The GenMark ePlex® System was designed with Patient Care in mind. By delivering rapid, comprehensive results, clinicians, patients, and their families can be assured that they are getting the right diagnosis in a timely manner. This results in better patient outcomes, hospital cost savings and improved patient satisfaction.
The right test at the right time during the SARS-CoV-2 pandemic
This respiratory illness season it may be more important than ever to understand when the cause of infection is SARS-CoV-2 or another respiratory pathogen. The symptoms and clinical presentation of respiratory infections are widely similar, complicating diagnosis, especially for those patients with underlying co-morbidities. Read this article to learn about the Importance of syndromic testing for respiratory illnesses, like COVID-19 and others.
What Our Customers are Saying
“Testing for upper respiratory infections using larger panels is essential, especially during flu season – it’s very challenging based on symptoms to narrow down the cause. It’s a big step in the right direction to be able to identify a pathogen without going on a fishing expedition. It helps us pick the right treatment and make the most appropriate bed management decisions, including who needs to be put on special precautions and isolation measures.” – Gregory J. Berry, Ph.D., D(ABMM), Director of Molecular Diagnostics, Northwell Health, New York City and Long Island. View Full Testimonial
“Having rapid identification allows you to implement policies based on results of the rapid PCR test without having to wait for susceptibilities. We implemented these policies with pharmacy which is the main driver of our antimicrobial stewardship program and saw that patients were being escalated in treatment based on a resistance marker detected or for organisms that were not covered by empirical treatment. We were also able to de-escalate patients from broad spectrum antimicrobials when the identified organism and clinical presentation strongly suggest a possible contaminant or an organism is known to be susceptible. Our capacity to cover gram-negatives extended more than 50-60 % with ePlex BCID Panels.” – Jose Alexander, MD, Clinical & Technical Director of the Microbiology, Virology and Immunology Laboratories, AdventHealth, Orlando, Orlando FL. View Full Testimonial
“Since implementing ePlex RP2 Panel, we went from a 7-to-10 day turnaround time to getting results in under two hours”. “Everybody feels comfortable using the analyzer – it’s the easiest one to use that I’ve ever seen.” – Teri Robertson, BSMT Laboratory Director, Graham Regional Medical Center, Graham, TX. View Full Testimonial
How can rapid comprehensive testing for Bloodstream Infections streamline results and improve patient care?
Opportunities Revealed for Antimicrobial Stewardship and Clinical Practice with Implementation of a Rapid Respiratory Multiplex Assay